Диссертация (Факторы риска развития анемии на ранних стадиях хронической болезни почек), страница 12
Описание файла
Файл "Диссертация" внутри архива находится в папке "Факторы риска развития анемии на ранних стадиях хронической болезни почек". PDF-файл из архива "Факторы риска развития анемии на ранних стадиях хронической болезни почек", который расположен в категории "". Всё это находится в предмете "медицина" из Аспирантура и докторантура, которые можно найти в файловом архиве МГМУ им. Сеченова. Не смотря на прямую связь этого архива с МГМУ им. Сеченова, его также можно найти и в других разделах. , а ещё этот архив представляет собой кандидатскую диссертацию, поэтому ещё представлен в разделе всех диссертаций на соискание учёной степени кандидата медицинских наук.
Просмотр PDF-файла онлайн
Текст 12 страницы из PDF
Милованов, Л.В. Козловская, Н.А.Мухин// Клиническая нефрология.- 2013.- № 2.- С. 10-18.23http://www.rusmedserv.com/files/labdiag/07_Anemii.pdf[Электронныйресурс]24Al–Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, LeveyAS, Sarnak MJ. Reduced kidney function and anemia as risk factors for79mortality in patients with left ventricular dysfunction. J Am Coll Cardiol.2001 Oct; 38(4):955–62.25Agarwal N., Prchal J.T.Anemia of chronic disease (anemia ofinflammation). Acta Haematol.
2009; 122(2–3): 103–108.26Armitage A.E., Eddowes L.A., Gileadi U. et al. Hepcidin regulation by innateimmune and infectious stimuli. Blood. 2011; 118:4129.27Bertero M.T., Caligaris-Cappio F. Anemia of chronic disorders in systemicautoimmune disease. Hematologica. 1997; 82: 375-381.28Boyce M, Warrington S, Cortezi B, et al. Safety, pharmacokinetics andpharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol inhealthy subjects. Br J Pharmacol 2016; 173:158029Brugnara C.
Iron deficiency and erythropoiesis: new diagnostic approaches.Clin Chem 2003; 49:157330Cash J.M., Slars D.A. The anemia of chronic disease: spectrum of associateddiseases in series of unselected hospitalized patients. Am. J. Med. 1989; 87:638.31Cooke K.S., Hinkle B., Salimi-Moosavi H. et al. A fully human anti-hepcidinantibody modulates iron metabolism in both mice and nonhuman primates.Blood. 2013; 122:3054.32Cullis J.O. Diagnosis and management of anaemia of chronic disease: currentstatus.
Br. J. Haemato.l 2011; 154:.289.33Felker G.M., Shaw L.K., Stough W.G., O'Connor C.M. Anemia in patientswith heart failure and preserved systolic function. Am Heart J. 2006 Feb; 151(2): 457-62.34Foley R.N., Parfrey P.S., Morgan J. et al. Effect of hemoglobin levelsin hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int2000; 58: 1325–133535Fung E, Nemeth E. Manipulation of the hepcidin pathway for therapeutic80purposes. Haematologica 2013; 98:166736Ganz T.
Hepcidin and iron regulation, 10 years later. Blood 2011; 117:442537Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu. Rev.Med. 2011; 62: 347-360.38Ganz T. Molecular pathogenesis of anemia of chronic disease. Pediatr BloodCancer 2006; 46:55439Ganz T., Nemeth E.
Iron sequestration and the anemia of inflammation.Semin. Hematol. 2009; 46: 387-393.40Ganz T, Olbina G, Girelli D, et al. Immunoassay for human serum hepcidin.Blood 2008; 112:429241Girelli D, Nemeth E, Swinkels DW. Hepcidin in the diagnosis of irondisorders. Blood 2016; 127:280942Gardenghi S., Renaud T.M., Meloni A.
et al. Distinct roles for hepcidin andinterleukin-6 in the recovery from anemia in mice injected with heat-killedBrucella abortus. Blood. 2014; 123:113743Infusino I, Braga F, Dolci A, Panteghini M. Soluble transferrin receptor(sTfR) and sTfR/log ferritin index for the diagnosis of iron-deficiencyanemia. A meta-analysis. Am J Clin Pathol 2012; 138:64244Kaltwasser JP, Hansen C, Oebike Y, Werner E: Assessment of ironavailability using stable Fe. Eur J Clin Invest 21 : 436 –442, 1991Cross Ref Medline Google Scholar45Kemna E, Pickkers P, Nemeth E, et al. Time-course analysis of hepcidin,serum iron, and plasma cytokine levels in humans injected with LPS.
Blood192005; 106:1864.46Kim A, Fung E, Parikh SG, et al. A mouse model of anemia of inflammation:complex pathogenesis with partial dependence on hepcidin. Blood. 2014;123:112947Kozlovskaya L.V., Milovanov Yu.S., Milovanova L.Yu. Optimal targetHemoglobin level in patients with chronic kidney disease and anemia treated81with erytropoiesis-stimulating agents: controversial issues. Arh.
Evromed.2011; 3: 87-91.48Koulaouzidis A, Said E, Cottier R, Saeed AA. Soluble transferrin receptorsand iron deficiency, a step beyond ferritin. A systematic review. JGastrointestin Liver Dis 2009; 18:34549Lasocki S., Longrois D., Montravera P., Beaumont C. Hepcidin and anemiain the critically ill patient: bench to bedside.
Anesthesiol. 2011; 114: 688694.50Libregts S.F., Gutiérrez L., de Bruin A.M. et al. Chronic IFN-γ production inmice induces anemia by reducing erythrocyte life span and inhibitingerythropoiesis through an IRF-1/PU.1 axis. Blood 2011; 118:2578.51Ludwiczek S., Aigner E., Theurl I., Weiss G. Cytokine-mediated regulationof iron transport in human monocytic cells.
Blood 2003; 101:4148.52McMahon S, Peto R, Cutler J, et al. Blood pressure, stroke and coronaryheart disease. Part 1. Prolonged differences in blood pressure: Prospectiveobservational studies corrected for the regression dilution bias. Lancet1990; 335: 765-7453Means RT Jr. Advances in the anemia of chronic disease. Int J Hematol 1999;70:754Means R.T. Jr. Recent developments in the anemia of chronic disease.
Curr.Hematol. Rep. 2003; 2:116.55Means R.T. Jr., Krantz S.B., Luna J. et al. Inhibition of murine erythroidcolony formation in vitro by interferon gamma and correction by interferonreceptor immunoadhesin. Blood. 1994; 83:911.56Moreland LW, Heck L W Jr, Koopman WJ. Biologic agents for treatingrheumatoid arthritis. Concepts and progress. Arthritis Rheum. 1997;40:397–409.57Mozaffarian, D.
Anemia predicts mortality in severe heart failure: theprospective randomized amlodipine survival evaluation (PRAISE) / D.82Mozaffarian, R. Nye, W.C. Levy // J Am Coll Cardiol. - 2003. – Vol. 41(11). – P. 1933193958Murphy S.T., Parfrey P.S. The impact of anemia correction on cardiovasculardisease in end-stage renal disease. Semin. Nephrol. 2000; 20: 350-355.59Nemeth E., Valore E.V., Territo M. et al. Hepcidin, a putative mediator ofanemia of inflammation, is a type II acute-phase protein. Blood. 2003;101:2461.60Nemeth E., Ganz T. Regulation of iron metabolism by hepcidin.
Annu. Rev.Nutr. 2006; 26 (1): 323–42.61Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K.,Ganz T. IL-6 mediates hypoferremia of inflammation by inducing thesynthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 2004; 113(9): 1251–3.62Nicolas G., Chauvet C., Viatte L. et al. The gene encoding the iron regulatorypeptide hepcidin is regulated by anemia, hypoxia, and inflammation. J. Clin.Invest. 2002; 110:103763NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic KidneyDisease: update. Am.
J. Kidney Dis. 2001;37(Suppl. 1):182-238.64Price E.A., Schrier S.L. Unexplained aspects of anemia of inflammation. AdvHematol 2010; 2010:50873965Punnonen K, Irjala K, Rajamäki A. Serum transferrin receptor and its ratio toserum ferritin in the diagnosis of iron deficiency. Blood 1997; 89:105266Raj DS. Role of interleukin-6 in the anemia of chronic disease. SeminArthritis Rheum 2009; 38:38267Reduced kidney function and anemia as risk factors for mortality in patientswith left ventricular dysfunction / A.
Al-Ahmad [et al.] // J Am Coll Cardiol.– 2001. - Vol. 38 (4). – P. 955-96268Revised European Best Practice Guidelines for the Management of anemia inPatientswithChronicRenalFailure.Nephrol.Dial.Transplant.832004;19(Suppl. 2):ii2-ii4569Roy CN. Anemia of inflammation. Hematology Am Soc Hematol EducProgram 2010; 2010: 27670Sasu B.J., Cooke K.S., Arvedson T.L.. et al. Antihepcidin antibody treatmentmodulates iron metabolism and is effective in a mouse model ofinflammation-induced anemia. Blood. 2010; 115:361671Sasu BJ, Li H, Rose MJ, et al.
Serum hepcidin but not prohepcidin may be aneffective marker for anemia of inflammation (AI). Blood Cells Mol Dis 2010;45:23872Schilling RF. Anemia of chronic disease: a misnomer. Ann Intern Med 1991;115:57273Steinbicker AU, Sachidanandan C, Vonner AJ, et al. Inhibition of bonemorphogenetic protein signaling attenuates anemia associated withinflammation. Blood 2011; 117:491574Theurl I, Aigner E, Theurl M, et al. Regulation of iron homeostasis in anemiaof chronic disease and iron deficiency anemia: diagnostic and therapeuticimplications. Blood 2009; 113:527775Theurl I, Mattle V, Seifert M, et al.
Dysregulated monocyte iron homeostasisand erythropoietin formation in patients with anemia of chronic disease.Blood 2006; 107:414276Theurl I., Schroll A., Sonnweber T. Pharmacologic inhibition of hepcidinexpression reverses anemia of chronic inflammation in rats. Blood. 2011;118:497777Theurl I., Theurl M., Seifert M. et al. Autocrine formation of hepcidininduces iron retention in human monocytes.
Blood. 2008; 111:239278Thomas C, Thomas L. Biochemical markers and hematologic indices in thediagnosis of functional iron deficiency. Clin Chem 2002; 48:106679van Eijk LT, John AS, Schwoebel F. et al. Effect of the antihepcidinSpiegelmer lexaptepid on inflammation-induced decrease in serum iron in84humans. Blood 2014; 124:264380Voulgari P.V., Kolios G., Papadopoulos G.K. et al. Role of cytokines in thepathogenesis of anemia of chronic disease in rheumatoid arthritis. Clin.Immunol. 1999; 92:153.81Weng, CH; Chen JB; Wang J; Wu CC; Yu Y; Lin TH. Surgically CurableNon-Iron Deficiency Microcytic Anemia: Castleman's Disease.. Onkologie.2011; 34 (8-9): 456–8.82Wrighting DM, Andrews NC.
